TC BioPharm Plots Clinical-Stage Strategy For CAR-Modified Gamma Delta T-Cells
Executive Summary
The UK cell therapy company has established cell therapy manufacturing facilities and plans clinical studies of CAR-modified gamma delta T-cells in cancer.
You may also be interested in...
Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics
Genentech and Lodo will mine the soil microbiome to discover novel therapeutics. China’s Luye licenses commercial rights to AstraZeneca’s Seroquel franchise, while Sarepta picked up rights to gene therapy candidates from Myonexus, plus an option to acquire the company.
Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.
Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Need a specific report? 1000+ reports available
Buy Reports